Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPN | P05981 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.41 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4231433 | 0.84 | PTPN1 (0.63) | PTPN1MAPTMEN1KMT2ASCN2A | |
| SCHEMBL1732116 | 0.78 | PTPN1 (1.00) | PTPN1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL1731402 | 0.77 | PTPN1 (0.96) | PTPN1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL1688153 | 0.77 | PTPN1 (0.66) | PTPN1MAPTMEN1KMT2AGAA | |
| SCHEMBL643464 | 0.77 | PTPN1 (0.66) | PTPN1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL1731203 | 0.77 | PTPN1 (0.66) | PTPN1 | |
| SCHEMBL6684475 | 0.77 | PTPN1 (0.66) | PTPN1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL6690418 | 0.75 | PTPN1 (0.73) | PTPN1ALDH1A1TSHRHTT | |
| SCHEMBL1730330 | 0.75 | CA12 (0.49) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5114118 | 0.74 | PTPN1 (0.43) | PTPN1MAPTMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057173-B1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8404731-B2 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120196906-A1 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PTPase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-7723369-B2 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100113331-A1 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PtPase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| EP-2057173-A1 | AMIDES AS SPHINGOMYELINE INHIBITORS | Novartis AG (CH) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008022771-A1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | disclosed |
| US-20070191385-A1 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | VTV THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022482-A1 | aSMase inhibitors | SMPD1, SMPD3, SMPD2 | PTPN1 2277/4885MAPT 3537/4885MEN1 2730/4885 |
| US-20070191385-A1 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | PTP4A1, PTPRJ, PTP4A2 | PTPN1 16/4885MAPT 3556/4885MEN1 4542/4885 |
| US-20100113331-A1 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PtPase Inhibitors | PTP4A1, PTPRJ, PTP4A2 | PTPN1 16/4885MAPT 3556/4885MEN1 4542/4885 |
| US-20120196906-A1 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PTPase Inhibitors | PTP4A1, PTPRJ, PTP4A2 | PTPN1 16/4885MAPT 3556/4885MEN1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.